---
title: "Bristol Myers Squibb hits 52-week high after FDA grants accelerated approval for myeloma drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296372697.md"
description: "Bristol Myers Squibb (BMY) rose 3% in regular trading to $67.82 after the FDA granted accelerated approval for its multiple myeloma therapy ZENBEXUS."
datetime: "2026-08-19T14:50:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296372697.md)
  - [en](https://longbridge.com/en/news/296372697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296372697.md)
generator: "portal-rs"
---

# Bristol Myers Squibb hits 52-week high after FDA grants accelerated approval for myeloma drug

百时美施贵宝 (BMY.US) 盘中股价创 52 周新高，现报**67.822**美元，涨超**2%**。

消息面上，美国 FDA 近日授予百时美施贵宝旗下多发性骨髓瘤治疗药物 ZENBEXUS（iberdomide）加速批准，用于联合达雷妥尤单抗和地塞米松治疗复发或难治性多发性骨髓瘤成人患者。该批准基于 EXCALIBER-RRMM 临床试验中观察到的**41%**微小残留病灶阴性完全缓解率。此外，公司近期与恒瑞医药达成全球合作，首付款价值高达**9.5 亿美元**，进一步巩固其在创新药领域的布局。

### Related Stocks

- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

- [RBC Capital Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)](https://longbridge.com/en/news/298666548.md)
- [Scotiabank Keeps Their Hold Rating on Bristol-Myers Squibb (BMY)](https://longbridge.com/en/news/298475819.md)
- [BMY Targets Pediatric MS Edge With New Ozanimod Study Against Fingolimod](https://longbridge.com/en/news/298624374.md)
- [Bristol Myers’ EVP, Chief Medical Officer Cristian Massacesi disposes of 6,249 common shares worth $403,700.93](https://longbridge.com/en/news/298642486.md)
- [BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM](https://longbridge.com/en/news/298442546.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**